|
DHG: Resolution of 2013 AGM DHG Pharmaceutical Joint Stock Company (DHG PHARMA) announced the resolution of 2013 annual general meeting as follows:
Article 1: Approving reports of the BOD. Consolidates business result and basic indicators
in 2009-2013:
|
No.
|
Items
|
Unit
|
2009
|
2010
|
2011
|
2012
|
2013
|
|
1
|
Total
assets
|
Billion dongs
|
1,522
|
1,820
|
1,996
|
2,378
|
3,081
|
|
2
|
Owner
equity
|
Billion dongs
|
1,018
|
1,280
|
1,382
|
1,688
|
1,981
|
|
3
|
Profit
after tax
|
Billion dongs
|
362
|
383
|
420
|
491
|
593
|
|
4
|
Profit
after tax of parent company’s shareholders
|
Billion dongs
|
357
|
381
|
416
|
486
|
589
|
|
5
|
EPS
|
VND
|
13,396
|
14,234
|
6,382
|
7,443
|
9,010
|
|
6
|
ROS
|
%
|
20.5
|
18.7
|
16.7
|
16.6
|
16.7
|
|
7
|
ROA
|
%
|
23.5
|
20.9
|
20.8
|
20.4
|
19.1
|
|
8
|
ROE
|
%
|
35.1
|
29.8
|
30.1
|
28.8
|
29.7
|
Results compared with the plan and growth
ratio in 2009-2013:
|
Items
(billion dongs)
|
2009
|
2010
|
2011
|
2012
|
2013
|
|
Plan
|
|
|
|
|
|
|
Net
revenue
|
1,500
|
1,920
|
2,240
|
2,750
|
3,200
|
|
Profit
before tax
|
150
|
310
|
380
|
505
|
570
|
|
Results
|
|
|
|
|
|
|
Net
revenue
|
1,746
|
2,035
|
2,491
|
2,931
|
3,527
|
|
Profit
before tax
|
410
|
434
|
491
|
585
|
782
|
|
Results/plan
|
|
|
|
|
|
|
Net
revenue
|
116%
|
106%
|
111%
|
107%
|
110%
|
|
Profit
before tax
|
273%
|
140%
|
129%
|
116%
|
137%
|
|
Growth
ratio
|
|
|
|
|
|
|
Net
revenue
|
17.5%
|
16.5%
|
22.4%
|
17.7%
|
20.3%
|
|
Profit
before tax
|
182.4%
|
6%
|
13.1%
|
19.1%
|
33.6%
|
Note: The 2009 profit before tax had 67.6
billion dongs refunded to a provision. The 2013 profit before tax had 122
billion dongs from transference of Eugica trademark and the company allotted 5%
of this (36 billion dongs) to Scientific and Technological Development Fund. Article 2: 2014-2018 business plan:
|
Items
(billion dongs)
|
2014
|
2015
|
2016
|
2017
|
2018
|
|
Net
revenue
|
3,880
|
4,420
|
5,216
|
6,199
|
7,400
|
|
Growth
of net revenue
|
10%
|
14%
|
18%
|
19%
|
19%
|
|
Profit
before tax
|
686
|
729
|
835
|
992
|
1,184
|
|
Growth
of profit before tax
|
6%
|
6%
|
14%
|
19%
|
19%
|
|
Ratio
of Profit before tax on Net revenue
|
17.7%
|
17%
|
16%
|
16%
|
16%
|
Note: The 2013 profit before tax used to the comparison
is 647 billion dongs excluding distribution to Scientific and Technological
Development Fund (36 billion dongs), financial income (48 billion dongs) and
extraordinary income from transference of Eugica trademark (122 billion dongs). Article 3: Approving an additional share
issuance to increase capital with 3:1 ratio - Stock name: shares of
DHG Pharmaceutical
Joint Stock Company - Stock type: common
stock - Par value:
VND10,000/share - Total volume: 65,376,429
shares - Currently outstanding
shares: 65,366,299 shares - Volume of treasury
shares: 10,130 shares - Additionally issued
volume: 21,788,766 shares - Total value: 217,887,660,000
dongs - Exercise ratio: 3:1
(the volume will be rounded) - Capital resource: Investment
and development fund - Subject: existing
shareholders -
Method
of the fraction part solution: keep back the Investment and development fund. Article 4:
Approving reports of 2013 profit distribution and remuneration as follows:
|
Items
|
2013 distribution ratio
|
Amount (VND)
|
|
Consolidated profit after tax (excluding
minorities’ interest)
|
|
588,959,753,802
|
|
Profit after tax of the parent company for
distribution
|
|
607,926,796,204
|
|
2013 dividend
|
Plan: 25% of par value (in cash)
Suggestion: 30% of par value (in cash)
|
228,782,042,500
|
|
- Paid 1/2013 dividend in cash (on 30 Aug. 2013)
|
15% of par value
|
98,049,448,500
|
|
- The 2/2013 dividend in cash after the issuance
|
15% of par value
|
130,732,598,000
|
|
Distribution to Bonus & welfare fund (*)
|
Plan: 10%
Suggestion: 12%
|
72,951,215,544
|
|
Compensation for the BOD, the Supervisory Board,
sub committees under the BOD, secretary board and 2013 key staff
|
According to the plan
|
5,000,000,000
|
|
Bonus for the BOD, the Supervisory Board, sub
committees under the BOD, secretary board and 2013 key staff
|
5% of growth of consolidated profit after tax
(according to the plan)
|
5,151,898,356
|
|
Remaining profit added to investment &
development fund
|
|
296,041,635,804
|
(*) Increasing the
distribution to bonus & welfare fund by 2% is for attention to employees’
families and 40-year foundation anniversaries. Article 5:
Approving the 2014 profit distribution:
|
Items
|
Distribution
ratio
|
|
2014 dividend ratio
|
25% par
value
|
|
Bonus &
welfare fund
|
10% profit
after tax
|
|
Remuneration of
the BOD, the Supervisory Board, and collaborators
|
5,000,000,000
dongs
|
|
Bonus for the BOD,
the Supervisory Board, and collaborators
|
5% of growth of consolidated profit after tax
(excluding the extraordinary income from transference of
Eugica trademark in 2013)
|
|
Remaining profit
|
Adding to
investment & development fund
|
Article
6: Approving revision of the Company’s regulation. Article 7: Authorizing
the BOD & the Supervisory Board to choose an auditing firm. Article 8:
Approving list of 07 members in the BOD for 2014-2018. Article 9: Voting
members of the BOD & the Supervisory Board again for 2014-2018: - Mr. Hoang Nguyen Hoc - Chairman of the BOD - Mr. Le Dinh Buu Tri - Deputy Chairman of the BOD - Ms. Pham Thị Viet Nga - Member of the BOD - Ms. Dang Pham Minh Loan - Member of the BOD - Mr. Doan Dinh Duy Khuong - Member of the BOD - Mr. Tran Chi Liem - Member of the BOD - Mr. Shuhei Tabata - Member of the BOD - Mr. Tran Quoc Hung – Head of the Supervisory Board - Ms. Nguyen Phuong Thao – Member of the Supervisory
Board - Mr. Dinh Duc Minh - Member of the Supervisory Board Article 10:
Appointing Ms. Pham Thi Viet Nga as the CEO as of 1 May 2014 (term in 03
years). Article 11:
Assigning the BOD & the CEO to implement these.
HOSE
|
